Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia

Description

This is an observational pilot study to examine the association between a patient's personality and adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Conditions

Chronic Myeloid Leukemia, Chronic Phase Chronic Myelogenous Leukemia

Talk to us

Study Overview

On this page

Study Details

Study overview

This is an observational pilot study to examine the association between a patient's personality and adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myeloid Leukemia

Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia

Condition
Chronic Myeloid Leukemia
Intervention / Treatment

-

Contacts and Locations

Orange

Chao Family Comprehensive Cancer Center University of California, Irvine, Orange, California, United States, 92868

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 18 years of age or older
  • * Diagnosed with chronic myeloid leukemia (CML) and in the chronic phase (CML-CP)
  • * Currently being treated with one of four cancer medications - imatinib, dasatinib, bosutinib, or nilotinib
  • * A patient at the UCI Chao Family Comprehensive Cancer Center (CFCCC), or
  • * A member of a patient support group organized by the CML Buster Foundation
  • * Do not meet any of the criteria listed under "Exclusion Requirements"
  • * Unable to read and speak English
  • * Impaired decisional capacity to consent

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, Irvine,

Mahtab Jafari, Pharm.D, PRINCIPAL_INVESTIGATOR, Chao Family Comprehensive Cancer Center

Study Record Dates

2026-01